Company Update (NYSE:LLY): Lilly to Present Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology

[PR Newswire] – INDIANAPOLIS, June 4, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will showcase results from three pivotal Phase 3 studies investigating ixekizumab for the treatment of moderate-to-severe plaque … . . . → Read More: Company Update (NYSE:LLY): Lilly to Present Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology Similar Articles: Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly Declares Second-Quarter 2015 Dividend Stock Update (NYSE:LLY): Lilly to Participate in Bank of America Merrill Lynch Health Care Conference Market Update (NYSE:LLY): Lilly Confirms Date and Conference Call for First-Quarter 2015 Financial Results Announcement